疾病介紹翻譯在醫(yī)院等醫(yī)療部門應(yīng)用比較廣泛，我們安徽譯博翻譯公司不僅擅長醫(yī)療翻譯，醫(yī)藥翻譯，疾病介紹翻譯，而且配有專業(yè)醫(yī)療翻譯人員，同時與多家大型醫(yī)療機構(gòu)保持合作關(guān)系，以下就是我公司譯員整理翻譯的關(guān)于肺癌介紹的相關(guān)重要知識的翻譯。
 
    Lung cancer is the most frequent and deadly malignancy worldwide and kills more people every year than colon, prostate, and breast cancer combined.Thus many efforts to improve diagnosis and therapy to increase the rate of lung cancer survival have been initiated during the last years.
 
    肺癌是世界上發(fā)病率最高且死亡威脅最大的疾病，每年因肺癌死亡的人數(shù)超過因結(jié)腸癌、前列腺癌和乳癌死亡人數(shù)的總和。為提高診斷和治療可能性從而降低肺癌死亡率，近年來開展了大量的研究。
 
    Lung cancer is classified as non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC accounts for approximately 20% of the new cases and differs clinically and biologically from the other histological types due to its neuroendocrine differentiation. The incidence of advanced disease at the time of primary diagnosis is high in SCLC. These tumors are, however, very sensitive to chemotherapy and radiotherapy.
 
    肺癌分為非小細(xì)胞癌（NSCLC）和小細(xì)胞癌（SCLC）。新發(fā)病例中，SCLC約占20％的比例，并因其神經(jīng)內(nèi)分泌分化與其它組織學(xué)型存在臨床和生物學(xué)差異。對于SCLC，初步診斷時進(jìn)展性肺癌的發(fā)病率高。但這些腫瘤對于化療和放療很敏感。
 
    Neuron specific enolase (NSE) has been the marker of choice in SCLC for prognosis, monitoring the course of disease and also for supporting diagnosis.However, NSE has relatively low sensitivity in early stage disease and is also influenced by hemolysis and other factors.
 
    神經(jīng)元特異烯醇化酶（NSE）已被選擇用作SCLC的標(biāo)記物，用于診斷和監(jiān)測病程，而且還用于診斷支持。
 
    The difference in NSE levels between healthy subjects, benign disease and SCLC is also relatively small. These limitations of NSE has stimulated the search for better markers and efforts to find effective combionations of markersfor SCLC.
 
    然而，對于早期肺癌，NSE的敏感性相對較低，還受溶血和其它因素的影響。健康個體之間以及良性肺癌和SCLC之間的NSE水平差別相對較小。NSE的這些局限性激起尋找更好的SCLC標(biāo)記物和有效組合標(biāo)記物的研究和試驗。
 
    The neuropeptide hormone Gastrin Releasing Peptide (GRP) was described more than 25 years ago as a tissue marker of SCLC, but it was not possible to measure GRP in blood due to its very short half-life. GRP is synthesised as a prohormone, ProGRP, and this precursor of GRP is stable in serum. Immunoassays for ProGRP have been developed and the determination of ProGRP (peptide 31-98) has been shown to be a useful serum marker for SCLC.
 
    25年前，神經(jīng)肽激素胃泌素釋放肽（GRP）被描述為SCLC的一種組織標(biāo)記物，但血液中的GRP因其半衰期很短無法測量。GRP被合成為一種激素原ProGRP，GRP的這種前體在血清中是穩(wěn)定的。ProGRP免疫測定已經(jīng)確立，ProGRP測定（肽31-98）證實ProGRP是一種有用的SCLC血清標(biāo)記物。

         我們真心希望可以以此幫助到同行業(yè)，或者醫(yī)院對 肺癌相關(guān)知識的翻譯與應(yīng)用。